Octocog alfa

Thông tin thuốc gốc
Chỉ định và Liều dùng
Treatment and prophylaxis of haemorrhagic episodes in patients with haemophilia A
Adult: Treatment: Dosage is individualised based on the severity of deficiency, location and extent of bleeding, and patient's clinical condition. Generally, admin of factor VIII 1 IU/kg will increase circulating factor VIII levels by approx 2 IU/dL. Recommendation: Minor bleeding: 10-20 IU/kg 12-24 hrly for approx 1-3 days. Moderate bleeding: 15-30 IU/kg 12-24 hrly for approx ≥3 days. Major bleeding: 30-50 IU/kg 8-24 hrly until bleeding resolves. Minor surgery: 30-50 IU/kg as a single dose w/in 1 hr of the procedure; repeat after 12-24 hr as needed. Major surgery: 40-60 IU/kg pre-op, repeated 8-24 hrly depending on state of wound healing. Prophylaxis: 20-40 IU/kg 3-4 times wkly. Doses are given via infusion over ≤5 min at max rate of 10 mL/min.
Child: Treatment: Same as adult dose. Patients <6 yr may require more frequent admin: 8-24 hrly (minor/moderate bleeding); 6-12 hrly (major bleeding); 6-24 hrly (major surgery). Prophylaxis: <6 yr 20-50 IU/kg 3-4 times wkly; ≥6 yr Same as adult dose.
Chống chỉ định
Hypersensitivity to mouse or hamster protein.
Thận trọng
Childn. Pregnancy and lactation.
Phản ứng phụ
Significant: Hypersensitivity reactions (e.g. anaphylaxis), inhibitory antibodies formation, catheter-related complications (e.g. bacteraemia, local infections, catheter-site thrombosis).
Nervous: Dizziness, headache, lightheadedness, asthenia, fatigue, malaise, depersonalisation, somnolence, restlessness, falling.
CV: Chest discomfort or tightness, increased/decreased BP.
GI: Diarrhoea, constipation, vomiting, dry mouth, unpleasant taste.
Resp: Nasopharyngitis, cough, rhinitis, dyspnoea, cough, nasal congestion, wheezing, epistaxis.
Musculoskeletal: Arthralgia, limb pain or injury, joint swelling.
Otic: Earache, ear infection.
Dermatologic: Facial flushing or swelling, rash, pruritus, urticaria.
Immunologic: Flu-like symptoms.
Others: Fever, chills, generalised discomfort, cold feet, inj site reactions (e.g. burning, erythema).
Monitor BP and heart rate before and during admin, plasma factor VIII activity before and during treatment; inhibitor occurrence, Hb, haematocrit, signs of bleeding, and hypersensitivity reactions.
Tác dụng
Description: Octocog alfa (coagulation factor VIII, recombinant) is a glycoprotein that is biologically equivalent to the factor VIII glycoprotein found in human plasma. It binds to endogenous von Willebrand Factor in the patient's circulation. Activated factor VIII activates factor X, as co-factor for activated factor IX. Activated factor X converts prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a stable clot.
Absorption: Time to peak plasma concentration: Approx 10-15 min, up to 1-2 hr.
Distribution: Circulates in plasma bound to von Willebrand factor; w/ minimal extravascular distribution (approx 14%).
Excretion: Terminal elimination half-life: 12 hr.
Bảo quản
Store between 2-8°C. Do not freeze.
Any unused portions should be disposed of in accordance w/ local requirements.
Phân loại MIMS
Advate (Baxalta US Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/05/2017 .

Anon. Antihemophilic Factor (Recombinant). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/05/2017 .

Buckingham R (ed). Factor VIII. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/05/2017 .

McEvoy GK, Snow EK, Miller J et al (eds). Antihemophilic Factor (Recombinant). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/05/2017 .

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Octocog alfa từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in